• Urothelial Bladder Cancer and Prostate Cancer — Proceedings from a Session Held in Conjunction with the 2025 ASCO Genitourinary Cancers Symposium (ASCO GU)

  • Mar 7 2025
  • Durée: 1 h et 58 min
  • Podcast

Urothelial Bladder Cancer and Prostate Cancer — Proceedings from a Session Held in Conjunction with the 2025 ASCO Genitourinary Cancers Symposium (ASCO GU)

  • Résumé

  • Featuring perspectives from Dr Terence Friedlander and Dr Matthew D Galsky, Dr Neeraj Agarwal and Dr Andrew J Armstrong, moderated by Dr Elisabeth I Heath, including the following topics:

    • Introduction (0:00)
    • Role of Antibody-Drug Conjugates (ADCs) in Front-Line Therapy for Metastatic Urothelial Bladder Cancer (mUBC) — Dr Friedlander (2:53)
    • Evidence-Based Use of ADCs for Relapsed/Refractory mUBC — Dr Galsky (33:04)
    • Evolving Role of Treatment Intensification with Androgen Receptor Pathway Inhibitors for Nonmetastatic and Metastatic Prostate Cancer — Dr Armstrong (1:01:28)
    • Optimal Integration of PARP Inhibitors into Therapy for Prostate Cancer — Dr Agarwal (1:27:49)

    CME information and select publications

    Voir plus Voir moins

Ce que les auditeurs disent de Urothelial Bladder Cancer and Prostate Cancer — Proceedings from a Session Held in Conjunction with the 2025 ASCO Genitourinary Cancers Symposium (ASCO GU)

Moyenne des évaluations de clients

Évaluations – Cliquez sur les onglets pour changer la source des évaluations.